Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

07.10.2024

1 Anticancer Drugs
1 BMC Cancer
2 Gynecol Oncol
1 J Clin Oncol
3 Lancet Oncol



    Anticancer Drugs

  1. MA L, Zhao X, Lu X, Shen J, et al
    KLF4 activates LATS2 to promote cisplatin sensitivity in ovarian cancer through DNA damage.
    Anticancer Drugs. 2024 Sep 27. doi: 10.1097/CAD.0000000000001662.
    >> Share


    BMC Cancer

  2. SHUANG T, Wu S, Zhao Y, Yang Y, et al
    The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian cancer cells.
    BMC Cancer. 2024;24:1213.
    >> Share


    Gynecol Oncol

  3. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
    Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
    Gynecol Oncol. 2024;191:86-94.
    >> Share

  4. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
    Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
    Gynecol Oncol. 2024;191:74-79.
    >> Share


    J Clin Oncol

  5. LEE JM, Brady MF, Miller A, Moore RG, et al
    Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
    J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683.
    >> Share


    Lancet Oncol

  6. SUNDAR S, Agarwal R, Davenport C, Scandrett K, et al
    Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study.
    Lancet Oncol. 2024;25:1371-1386.
    >> Share

  7. TASKIRAN C, Canturk MM
    Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer.
    Lancet Oncol. 2024;25:1251-1252.
    >> Share

  8. PENG Z, Li H, Gao Y, Sun L, et al
    Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2024;25:1288-1297.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016